1-methyl-3-phenyl-Δ³-1,2,4-triazolin-5-one | 54034-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-methyl-3-phenyl-Δ³-1,2,4-triazolin-5-one
• 英文别名: 2-methyl-5-phenyl-1,2-dihydro-[1,2,4]triazol-3-one；2-Methyl-5-phenyl-1,2-dihydro-[1,2,4]triazol-3-on；1-Methyl-3-phenyl-Δ³-s-triazolin-5-on；3H-1,2,4-Triazol-3-one, 1,2-dihydro-2-methyl-5-phenyl-；2-methyl-5-phenyl-4H-1,2,4-triazol-3-one
• CAS: 54034-38-7
• 化学式: C₉H₉N₃O
• 分子量: 175.19
• InChiKey: VVUPNBPFNVLLEH-UHFFFAOYSA-N

物化性质

• 熔点：
  219 °C
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯甲亚胺酸乙酯 在 2,4,6-三甲基吡啶 作用下， 以 四氯化碳 、 正己烷 为溶剂， 反应 48.0h， 生成 1-methyl-3-phenyl-Δ³-1,2,4-triazolin-5-one
  参考文献：
  名称：

  Regioselective Synthesis of 1,2,4-Triazole and 1,2,4-Oxadiazole Derivatives

  摘要：

  DOI：

  10.1055/s-1983-30394

文献信息

• CGRP ANTAGONISTS
  申请人：Gottschling Dirk

  公开号：US20110059954A1

  公开（公告）日：2011-03-10

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 and R 3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的新的CGRP拮抗剂，其中U、V、X、Y、R1、R2和R3如下所述定义，其互变异构体、同分异构体、对映异构体、水合物、混合物及其盐和盐的水合物，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及制备它们的过程。
• Thermal behaviour of 3-phenyl-1,2,4-oxadiazol-5-ylhydrazines
  作者：Giorgio Adembri、Alfredo Camparini、Fabio Ponticelli、Piero Tedeschi

  DOI：10.1039/p19810001703

  日期：——

  Depending on the substitution on the hydrazine moiety, thermolysis of 3-phenyl-1,2,4-oxadiazol-5-ylhydrazines (1)–(5) gives variable amounts of 1-amino-Δ2-1,2,4-triazolin-5-ones (13) or (17), Δ2- or Δ3-1,2,4-triazolin-5-ones (12), (18), or (19), and the s-triazine (20). A possible mechanism accounting for the products and the effects is discussed. A diradical intermediate and a hydrogen transfer from

  根据在肼基部分的取代，3-苯基-1,2,4-恶二唑-5- ylhydrazines热解（1） - （5）给出了不同量的1-氨基- Δ的2 -1,2,4-三唑啉-5-酮（13）或（17），Δ 2 -或Δ 3 -1,2,4-三唑啉-5-酮（12），（18）或（19），并且š嗪（ 20）。讨论了一种可能的解释产品及其效果的机制。根据过氧化苯甲酰对反应的影响以及肼（1）–（4）催化加氢的行为，提出了双自由基中间体和氢从反应介质中的转移。
• SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：MUELLER Stephan Georg

  公开号：US20090253680A1

  公开（公告）日：2009-10-08

  The present invention relates to the CGRP-antagonists of general formula I wherein R 1 , R 2 , R 3 and R 4 are defined as in claim 1 , the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的CGRP拮抗剂，其中R1、R2、R3和R4如权利要求1所定义，其互变异构体、异构体、对映异构体、立体异构体、水合物、混合物及其盐和其盐的水合物，特别是与无机或有机酸或碱的生理可接受盐，以及其中一个或多个氢原子被氘取代的一般式I化合物，包含这些化合物的制药组合物，它们的用途和制备它们的过程。
• Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
  申请人：Almstead Neil

  公开号：US20080280869A1

  公开（公告）日：2008-11-13

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过给予本发明的化合物或组合物来治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
• PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES
  申请人：PTC THERAPEUTICS, INC.

  公开号：US20150274674A1

  公开（公告）日：2015-10-01

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及使用本发明中的化合物或组合物治疗或预防与mRNA中的无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及用于抑制与mRNA中的无意义突变相关的早期翻译终止的方法、化合物和组合物。